China Shineway Pharmaceutical Group Limited - Asset Resilience Ratio
China Shineway Pharmaceutical Group Limited (C1S) has an Asset Resilience Ratio of 3.49% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check China Shineway Pharmaceutical Group Limi (C1S) strategic investment index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2025)
This chart shows how China Shineway Pharmaceutical Group Limited's Asset Resilience Ratio has changed over time. See China Shineway Pharmaceutical Group Limi balance sheet quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down China Shineway Pharmaceutical Group Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see C1S stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €376.64 Million | 3.49% |
| Total Liquid Assets | €376.64 Million | 3.49% |
Asset Resilience Insights
- Limited Liquidity: China Shineway Pharmaceutical Group Limited maintains only 3.49% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
China Shineway Pharmaceutical Group Limited Industry Peers by Asset Resilience Ratio
Compare China Shineway Pharmaceutical Group Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
SIMCERE PHARMAC. GRP LTD
F:S2P |
Drug Manufacturers - Specialty & Generic | 0.44% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
Annual Asset Resilience Ratio for China Shineway Pharmaceutical Group Limited (2017–2025)
The table below shows the annual Asset Resilience Ratio data for China Shineway Pharmaceutical Group Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 3.49% | €376.64 Million ≈ $440.33 Million |
€10.78 Billion ≈ $12.60 Billion |
+0.01pp |
| 2024-12-31 | 3.49% | €350.02 Million ≈ $409.21 Million |
€10.04 Billion ≈ $11.74 Billion |
+3.28pp |
| 2023-12-31 | 0.21% | €20.00 Million ≈ $23.38 Million |
€9.57 Billion ≈ $11.19 Billion |
-0.04pp |
| 2022-12-31 | 0.25% | €20.23 Million ≈ $23.65 Million |
€8.23 Billion ≈ $9.62 Billion |
+0.14pp |
| 2018-12-31 | 0.11% | €7.19 Million ≈ $8.41 Million |
€6.73 Billion ≈ $7.87 Billion |
-0.15pp |
| 2017-12-31 | 0.25% | €16.91 Million ≈ $19.77 Million |
€6.67 Billion ≈ $7.79 Billion |
-- |
About China Shineway Pharmaceutical Group Limited
China Shineway Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and trade of Chinese pharmaceutical products in the People's Republic of China and Hong Kong. The company offers Chinese medicines in the form of injection, soft capsules, and granules; tablets, pills, oral liquid, and powder; and traditional Chinese medicine granules … Read more